3-(1,2,3,4,5,8-Hexahydroindolizin-7-yl)-5-fluoro-1H-indole | 214626-16-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(1,2,3,4,5,8-Hexahydroindolizin-7-yl)-5-fluoro-1H-indole
• 英文别名: 3-(1,2,3,5,8,8a-hexahydroindolizin-7-yl)-5-fluoro-1H-indole
• CAS: 214626-16-1
• 化学式: C₁₆H₁₇FN₂
• 分子量: 256.323
• InChiKey: WRYSHDPNNMSQDL-UHFFFAOYSA-N

物化性质

• 沸点：
  438.0±45.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  19
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-氟吲哚 、 indolizin-7-one 生成 3-(1,2,3,4,5,8-Hexahydroindolizin-7-yl)-5-fluoro-1H-indole
  参考文献：
  名称：

  Substituted heteroaromatic 5-HT 1F agonists

  摘要：

  这项发明提供了一种新型的5-HT1F激动剂，其化学式为X、Y、E、R、A、B和n如规范中所定义，可用于治疗偏头痛及相关疾病。

  公开号：

  EP0875513A1

文献信息

• Substituted heteroaromatic 5-HT 1F agonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP0875513A1

  公开（公告）日：1998-11-04

  This invention provides novel 5-HT1F agonists of the Formula in which X, Y, E, R, A, B, and n are as defined in the specification, which are useful for the treatment of migraine and associated disorders.

  这项发明提供了一种新型的5-HT1F激动剂，其化学式为X、Y、E、R、A、B和n如规范中所定义，可用于治疗偏头痛及相关疾病。
• Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity
  申请人：Torrens Jover Antoni

  公开号：US20070009597A1

  公开（公告）日：2007-01-11

  The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT 6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合，包括至少一种具有神经肽Y受体亲和力的化合物，优选为神经肽Y5受体亲和力，以及至少一种具有5-HT6受体亲和力的化合物，一种包含该活性物质组合的药物，以及使用该活性物质组合制造药物。
• 1-Sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands
  申请人：Merce Vidal Ramon

  公开号：US20070060581A1

  公开（公告）日：2007-03-15

  The present invention refers to new sulfonamide derivatives, of general formula (Ia, Ib, Ic), (I), (Ia, Ib, Ic), optionally in form of one of their stereoisomers, preferably enantiomers or diastereomers, their racemate, or in form of a mixture of at least two of their stereoisomers, preferably enantiomers or diastereomers, in any mixing ratio, or their salts, preferably their corresponding physiologically acceptable salts or corresponding solvates; to the processes for their preparation, to their application as medicaments in human and/or veterinary therapeutics, and to the pharmaceutical compositions containing them. The new compounds of the present invention can be used in the pharmaceutical industry as intermediates and for preparing medicaments.

  本发明涉及新的磺酰胺衍生物，通式为(Ia，Ib，Ic)，(I)，(Ia，Ib，Ic)，可以是它们的立体异构体之一，优选对映异构体或顺反异构体，它们的外消旋体，或者是至少两种立体异构体的混合物，优选对映异构体或顺反异构体，在任何混合比例下，或者它们的盐，优选它们的相应生理上可接受的盐或相应溶剂化合物；以及它们的制备方法，它们在人类和/或兽医治疗中作为药物的应用，以及包含它们的制药组合物。本发明的新化合物可用于制药工业中作为中间体和制备药物。
• ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY
  申请人：Torrens Jover Antoni

  公开号：US20120128768A1

  公开（公告）日：2012-05-24

  The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity and at least one compound with 5-HT6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种活性物质组合物，包括至少一种具有神经肽Y受体亲和力的化合物和至少一种具有5-HT6受体亲和力的化合物，以及包含该活性物质组合物的药物和使用该活性物质组合物制造药物的用途。
• BICYCLIC PIPERIDINE AND PIPERAZINE COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY
  申请人：NPS Allelix Corp.

  公开号：EP1105393B1

  公开（公告）日：2003-10-01